Investor Presentation
Brisbane, Oct 13, 2016 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
Presentation highlights include:
- Data on the growing need for a safe and effective alternative to the use of antibiotics in the production of livestock animals and in humans, in line with the United Nations' statement in September 2016 that drug resistance is "the greatest and most urgent global risk"
- The clear path to launch for Detach(TM), Anatara's natural, non-antibiotic therapeutic to prevent gastrointestinal diseases in pigs, following the Company's recent application to register the product for marketing with the Australian Pesticides and Veterinary Medicines Authority
- An overview of the competitive landscape for other therapeutics used to treat gastrointestinal disease in pigs
- A status update on the Company's efforts to move its technology from pigs into humans, along with the commercial rationale for doing so.
To view the presentation, please visit:
http://abnnewswire.net/lnk/ZV0A096W
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
